CytomX Therapeutics — Q3 2026 Earnings Summary

CytomX Therapeutics announced Q3 2026 financial results showing total revenue of $1.7 million and a net loss of $19.998 million for the quarter. The company's cash, cash equivalents, and investments totaled $348.0 million as of September 30, 2026, providing a runway into the second half of 2028. Varsetatug masetecan received FDA Fast Track designation for relapsed or refractory metastatic colorectal cancer, with Phase 1 monotherapy data updates expected in January 2027. Additionally, the company initiated Phase 1 expansion cohorts for Varsetatug masetecan in gastric, pancreatic, and biliary tract cancers while continuing enrollment for its second candidate, CX-801, in advanced melanoma.